ALLERGAN AUSTRALIA PTY LIMITED

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Comparison of Efficacy and Safety of Two Different Types of Botulinum Toxin Type A in Moderate to Severe Cervical Dystonia

Phase 4

Completed

Conditions: Spasmodic Torticollis

Interventions: Biological: botulinum toxin type A

First Posted Date: 2007-09-12

Last Posted Date: 2011-12-16

Lead Sponsor: Allergan

Target Recruit Count: 145

Registration Number: NCT00528541

A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With Cataract Surgery

Phase 3

Completed

Conditions: Cataract Extraction
Pain
Inflammation

Interventions: Drug: ketorolac

First Posted Date: 2007-09-03

Last Posted Date: 2009-10-01

Lead Sponsor: Allergan

Target Recruit Count: 248

Registration Number: NCT00524264

A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With Cataract Surgery

Phase 3

Completed

Conditions: Cataract Extraction

Interventions: Drug: ketorolac eye drops

First Posted Date: 2007-08-27

Last Posted Date: 2009-10-01

Lead Sponsor: Allergan

Target Recruit Count: 263

Registration Number: NCT00521456

A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis

Phase 3

Completed

Conditions: Bacterial Conjunctivitis

Interventions: Drug: Gatifloxacin 0.5% eye drops
Drug: placebo eye drops

First Posted Date: 2007-08-20

Last Posted Date: 2019-04-23

Lead Sponsor: Allergan

Target Recruit Count: 859

Registration Number: NCT00518089

Safety and Efficacy of an Artificial Tear for the Treatment of Dry Eye

Not Applicable

Completed

Conditions: Dry Eye Syndrome

Interventions: Drug: Carboxymethylcellulose and Glycerin based artificial tear
Drug: Carboxymethylcellulose

First Posted Date: 2007-08-10

Last Posted Date: 2009-12-15

Lead Sponsor: Allergan

Target Recruit Count: 316

Registration Number: NCT00514852

Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)

Phase 2

Completed

Conditions: Choroidal Neovascularization
Age-Related Maculopathy

Interventions: Biological: ranibizumab
Drug: dexamethasone
Other: sham

First Posted Date: 2007-08-06

Last Posted Date: 2019-04-25

Lead Sponsor: Allergan

Target Recruit Count: 243

Registration Number: NCT00511706

A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis

Phase 3

Completed

Conditions: Bacterial Conjunctivitis

Interventions: Drug: Gatifloxacin 0.5% eye drops
Drug: placebo eye drops

First Posted Date: 2007-08-01

Last Posted Date: 2011-11-30

Lead Sponsor: Allergan

Target Recruit Count: 578

Registration Number: NCT00509873

Internet-based, Naturalistic Evaluation of Tolerability and Individual Patient Target Pressures With Bimatoprost 0.03% in Glaucoma

Completed

Conditions: Glaucoma, Open-Angle

First Posted Date: 2007-06-15

Last Posted Date: 2011-06-01

Lead Sponsor: Allergan

Target Recruit Count: 361

Registration Number: NCT00487214

Safety and Efficacy of a New Treatment in Combination With Laser for Diabetic Macular Edema

Phase 2

Completed

Conditions: Diabetic Macular Edema

Interventions: Drug: Sham injection
Drug: Dexamethasone
Procedure: Laser Photocoagulation

First Posted Date: 2007-04-24

Last Posted Date: 2019-04-24

Lead Sponsor: Allergan

Target Recruit Count: 253

Registration Number: NCT00464685

A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis

Phase 4

Completed

Conditions: Bacterial Conjunctivitis

Interventions: Drug: gatifloxacin
Drug: moxifloxacin 0.5% eye drops

First Posted Date: 2007-04-23

Last Posted Date: 2011-09-21

Lead Sponsor: Allergan

Target Recruit Count: 171

Registration Number: NCT00464438

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy